Kajdácsi, Erika http://orcid.org/0000-0003-0739-2193
Veszeli, Nóra http://orcid.org/0000-0002-7647-2173
Mező, Blanka http://orcid.org/0000-0002-9750-1682
Jandrasics, Zsófia
Kőhalmi, Kinga Viktória http://orcid.org/0000-0002-7381-6866
Ferrara, Anne Lise http://orcid.org/0000-0003-1839-8873
Cervenak, László http://orcid.org/0000-0003-0166-8697
Varga, Lilian http://orcid.org/0000-0002-5484-364X
Farkas, Henriette
Funding for this research was provided by:
Nemzeti Kutatási, Fejlesztési és Innovaciós Alap (K124557)
Semmelweis University
Article History
Accepted: 26 January 2021
First Online: 19 February 2021
Declarations
:
: The study protocol was approved by the institutional review board of Semmelweis University of Budapest, and informed consent was obtained from all the participants in accordance with the Declaration of Helsinki.
: KVK received honoraria and travel grants from CSL Behring and Shire and has participated in clinical trials of BioCryst, CSL Behring, Pharming, and Shire. LV received travel grants from CSL Behring and Shire Human Genetic Therapies Inc. HF received honoraria and travel grants from CSL Behring, Shire/Takeda, Swedish Orphan Biovitrum, Octapharma, Kalvista and Pharming; and/or served as a consultant for these companies and has participated in clinical trials/registries for BioCryst, CSL Behring, Pharming, and Shire. Other authors have declared no conflict of interest.